Department of Clinical Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia ; Department of Pharmacology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Saudi Pharm J. 2012 Jan;20(1):81-4. doi: 10.1016/j.jsps.2011.06.001. Epub 2011 Jun 15.
To evaluate the efficacy and tolerability of Levetiracetam (LEV) as an adjunctive therapy in pediatric patients with different generalized epilepsies.
Chart review of 22 consecutive children age 4-19 years who were treated with LEV for at least 1 year was observed retrospectively. The mean dose rang of LEV was from 250 to 2000 mg. Data were collected on epilepsy type, seizure frequency, concomitant antiepileptic drug and adverse effect.
Of the 22 patient reviewed, 13 (59%) were boys and 9 (41%) were girls. Predominant seizure types were generalized tonic-clonic seizures 13 (59%) and tonic seizure 6 (27%). Other seizure types included myoclonic seizures 2 (9%) and focal seizure 3 (5%). The results showed 10 (45%) had become free of seizure for almost 7 months to 1 year. Eight of these 10 patients (80%) had normalized EEG. Seizure frequency was reduced in 9 (41%) patients and 3 (14%) patients still had seizure. No side effects were reported related to LEV treated patients except for 1 patient.
Our results confirm that LEV may be an effective adjunctive therapy in treatment of childhood epilepsy, especially tonic-clonic seizure, with possible no evident side effect.
评估左乙拉西坦（LEV）作为辅助治疗儿科不同全面性癫痫的疗效和耐受性。
回顾性观察了 22 例连续接受 LEV 治疗至少 1 年的 4-19 岁儿童患者的图表。LEV 的平均剂量范围为 250 至 2000mg。收集了癫痫类型、发作频率、合用抗癫痫药物和不良反应的数据。
在 22 例患者中，13 例（59%）为男孩，9 例（41%）为女孩。主要发作类型为全面强直阵挛发作 13 例（59%）和强直发作 6 例（27%）。其他发作类型包括肌阵挛发作 2 例（9%）和局灶性发作 3 例（5%）。结果显示，10 例（45%）患者在近 7 个月至 1 年内几乎无发作。这 10 例患者中有 8 例（80%）脑电图正常。9 例（41%）患者发作频率降低，3 例（14%）患者仍有发作。除 1 例患者外，未报告与 LEV 治疗相关的不良反应。
我们的结果证实，LEV 可能是治疗儿童癫痫的一种有效辅助治疗方法，特别是强直阵挛发作，可能没有明显的副作用。
